Design Therapeutics (DSGN) Long-Term Deferred Tax (2020)

Design Therapeutics (DSGN) reported Long-Term Deferred Tax of $212000.0 for Q4 2020.

Design Therapeutics (DSGN) Long-Term Deferred Tax (2020) Analysis & Trends

Design Therapeutics (DSGN) has 1 years of Long-Term Deferred Tax data on file, last reported at $212000.0 in Q4 2020.

For the quarter ending Q4 2020, Long-Term Deferred Tax changed N/A year-over-year to $212000.0; the trailing twelve-month figure through Dec 2020 stood at $212000.0 (changed N/A YoY), and the FY2020 full-year result was $212000.0, changed N/A from the prior year.
Long-Term Deferred Tax held at $212000.0 in Q4 2020.
In the past five years, Long-Term Deferred Tax ranged from a high of $212000.0 in Q4 2020 to a low of $212000.0 in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Design Therapeutics	714.48 Mn	491.66 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	212,000.00